Skip to main content
Fig. 2 | Health and Quality of Life Outcomes

Fig. 2

From: Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Fig. 2

Change in OAB-S scales over time: a Impact on Daily Living with OAB; b OAB Control; c Satisfaction with OAB Control; and change in OAB-S single items: d Patient’s Fulfillment of OAB Medication Expectations; e Interruption of Day-to-Day Life Due to OAB; f Overall Satisfaction with OAB Medication; g Improvement in Day-to-Day Life Due to OAB Medication; h Willingness to Continue OAB Medication

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us